Thanks to the efforts of Governor Kathy Hochul, Cornell University’s College of Veterinary Medicine has commenced a ...

A new report from the St. Louis Fed shows that economic output is trending higher, even though employee head-count has barely moved. A few years ago, you might have blamed pent-up demand or a ...

Prevent Microsoft 365 Copilot from exposing confidential files through inherited SharePoint permissions. Practical audit and fix guide for UK mid-market IT team ...

Google announced a partnership with ISTE+ASCD to provide free Gemini AI training to all 6 million K-12 and higher education faculty in the United States. The initiative is the largest AI literacy ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

Thousands of IT admins were locked out as a Microsoft 365 admin center outage disrupted access for North American businesses. Microsoft 365 going down again is starting to feel less like breaking news ...

A feasibility study analyzes all of the critical aspects of a proposed project. Understand how these studies work, how to conduct them, and the benefits involved.

Are you among those who receive the frustrating error message “You must start Microsoft Access by double-clicking a Microsoft Access file” when trying to open the ...

According to God of Prompt on Twitter, the new n8n automations bundle now includes over 10 pre-built workflows and video tutorials, with lifetime access and updates currently available before ...

Health and Fitness is the dominant topic on mobile Copilot. On desktop, “Work and Career” overtakes “Technology” as the top topic between 8 a.m. and 5 p.m. The researchers say mobile use includes ...

New integrations with industry leaders in EDC, eConsent, IRT/RTSM, eCOA, payments, and patient engagement expands Advarra's connected ecosystem, giving sponsors, CROs, and research sites secure, ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...